In a phase II trial (NCT01795768), the FGFR1/2/3 inhibitor AZD4547 demonstrated potential therapeutic effects in patients with FGFR1-amplified breast tumors (102) (Table 4). The gene discussed is FGFR1; the disease is breast neoplasm.